Moĭseenko V M, Orlova R V, Ermakova N A, Protsenko S A
N.N. Petrov Research Institute of Oncology, Ministry of Health of the RF, St. Petersburg.
Vopr Onkol. 2000;46(5):600-3.
Miltex (miltefosine) is a new antiproliferation drug comprising phospholipid ingredients. It is used for topical treatment of metastatic skin lesions in breast cancer. Clinical trials of the drug were conducted in 11 breast cancer patients resistant to standard therapy. Apparent therapeutic effect (partial regression) was registered in 27.3% (3/11). Moderate toxic effects were generally confined to skin itching (36.4%) and scaling (18.2%), erythema (18.2%), and paper skin (45.5%).
米尔特司（米替福新）是一种含有磷脂成分的新型抗增殖药物。它用于局部治疗乳腺癌的转移性皮肤病变。该药物在11例对标准疗法耐药的乳腺癌患者中进行了临床试验。27.3%（3/11）的患者出现明显治疗效果（部分消退）。中度毒性反应一般局限于皮肤瘙痒（36.4%）、脱屑（18.2%）、红斑（18.2%）和皮肤干燥（45.5%）。
